Accomplishments

Recognition

 

  • Boca Magazine (2017) Business Profile – Alicia Sable-Hunt, RN, MBA, CCRA
  • Wilen-Daugenti, T., Vien, C.L., Molina-Ray, C. (2012) WOMEN LEAD Career Perspectives from Workplace Leaders. New York: Peter Lang.
  • Ettlinger, C. “Taking Care of Business: Taking a Bite Out of Cancer, Alicia Sable-Hunt.” scrubs magazine Summer 2012:26-27. Print.
  • Dowd-Higgins, C. (2011). This Is Not the Career I Ordered Empowering Strategies from Women Who Recharged, Reignited, and Reinvented Their Careers. Bloomington, IN: Reinvention Press.
  • Graham, K. (2010). Weight Loss EMPOWERMENT: Sable’s Foods – The Cancer Nutrition Challenge. 
  • FasterCure’s Who’s Who of Biobanking. 2005.

Publications

  • Barbara J. Gitlitz, Deborah Morosini, Alicia L. Sable-Hunt, Bonnie J. Addario, Stacy L. Mach, Mark Byron Jennings, S. Lani Park, Marisa A Bittoni, Geoffrey R. Oxnard. The Genomics of Young Lung Cancer Study. ASCO Poster, 2016. 
  • Barbara J. Gitlitz, Deborah Morosini, Alicia L. Sable-Hunt, Bonnie J. Addario, Mark Byron Jennings, Stacy L. Mach, Geoffrey R. Oxnard. The genomics of Young Lung Cancer Study. 2015 American Society of Clinical Oncology, Annual Meeting May 29-June 2, 2015. J Clin Oncol 33, 2015 (suppl; abstr TPS11110)
  • Barbara J. Gitliz, Deborah Morosini, Alicia Sable-Hunt, Bonnie J Addario, Geoffrey R. Oxnard. The Genomics of Young Lung Cancer Study. American Associated for Cancer Research. Translation of the Cancer Genome, San Francisco, California, February 2015
  • Geoffrey R. Oxnard, Jennifer C. Heng, Elizabeth J. Root, Irene R. Rainville, Alicia L. Sable-Hunt, Kate P Shane-Carson, David Paul Carbone, Georgia L. Wiesner, Judy Ellen Garber. Initial results of a prospective, multicenter trial to study inherited lung cancer risk associated with germline EGFR T790M: INHERIT EGFR. ASCO Poster, 2015.
  • Gitlitz, B.J., Morosini, D., Sable-Hunt, A.L., Addario, B.J., Oxnard, G.R. The Genomics of Young Lung Cancer Study. ASCO Poster, 2015.
  • Oxnard, G.R., Heng, J., Rainville, I., Root, E., Dahlberg, S.E., Sable-Hunt, A.L., Wiesner, G.L., Taylor, K.A., Jackman, D.M., Janne, P.A., Garber, J.E. The INHERIT EGFR study: Investigating Hereditary Risk from T790M. AACR Poster, 2013.
  • Oxnard, G.R., Heng, J., Rainville, I., Root, E., Dahlberg, S.E., Sable-Hunt, A.L., Wiesner, G.L., Taylor, K.A., Jackman, D.M., Janne, P.A., Garber, J.E. The INHERIT EGFR study: Investigating Hereditary Risk from T790M. ASCO Poster, 2013.
  • Sable-Hunt, A. (2013). Clinical Trials. In Bonnie J. Addario Lung Cancer Foundation Navigating Lung Cancer 360 of Hope. San Carlos, CA. 
  • Sable-Hunt, A. (2010). Sable’s Foods – The Cancer Nutrition Challenge. In Weight Loss EMPOWERMENT (pp. 231, 232). Rancho Santa Margarita, CA: Grande Gringos, Inc.
  • Ahmann, G., Chng, WJ., Henderson, K., Price-Troska, TL., DeGoey, RW., Timm, MM., Dispenzieri, A., Greipp, PR., Sable-Hunt, A., Bergsagel, L., Fonseca, R. Impact of Tissue Shipping on Plasma Cell Isolation, Viability, and RNA Integrity in the Context of a Centralized Good Laboratory Practice Certified Tissue Banking Facility. AACR 2008. 
  • Stewart, AK, Chang, H., Trudel, S., Anderson, KC, Richardson, P., Alsina, M., Reece, D., Young, S., Sable-Hunt, A., Li, Z., Keats, J., Van Wier, S., Ahmann, G., Price-Troska, T., Giusti, K., Bergsagel, PL, Chesi, M., Fonseca, R. (2007). Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia, 21(11): 10.1038. NIHMSID: NIHMS181755. PMCID: PMC3882151
  • Stewart, K., Tudel, S., Chang, H., Anderson, K., Richardson, P., Alsina, M., Reece, D.E., Greipp, P., Young, S., Sable-Hunt, A., Li, Z.H., Keats, J., Van Wier, S., Ahmann, G., Price-Troska, T., Giusti, K., Fonseca, R. Diagnostic Evaluation of t[4;14] in Multiple Myeloma. ASH Poster, December 2006. 
  • Sable-Hunt, A. (2006). Case study: Multiple Myeloma Research Consortium. LabVantage Solutions.
  • R. C. Frank, A. Coscia, L. Versea, N. Cohen, R. Zelkowitz, A. Ruskin, A. Skeris (Sable-Hunt), P. Dodds and K. Nair. Low dose docetaxel, estramustine and thalidomide followed by maintenance thalidomide for the treatment of hormone refractory prostate cancer (HRPC): A phase II community based trial.  J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 4681.

CCRA Certification